Medco Partners With MolecularMD on Personalized Medicine Program for Chronic Myeloid Leukemia

Medco Health Solutions, Inc. MHS and MolecularMD Corp. today announce the launch of a personalized medicine program for chronic myeloid leukemia patients. Through this program, Medco will offer patients diagnosed with CML a molecular test known as qRT-PCR BCR-ABL to monitor the disease.